These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38543908)

  • 1. Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases.
    Yap RXL; Lai YW; Wei C; Ng JJW; Xu D; Feng S; Mu R; Thong BY; Xu C
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.
    Furer V; Eviatar T; Freund T; Peleg H; Paran D; Levartovsky D; Kaufman I; Broyde A; Elalouf O; Polachek A; Feld J; Haddad A; Gazitt T; Elias M; Higazi N; Kharouf F; Gertel S; Pel S; Nevo S; Hagin D; Zisman D; Elkayam O
    Ann Rheum Dis; 2022 Nov; 81(11):1594-1602. PubMed ID: 35868846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.
    Sieiro Santos C; Calleja Antolin S; Moriano Morales C; Garcia Herrero J; Diez Alvarez E; Ramos Ortega F; Ruiz de Morales JG
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
    Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
    Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions.
    Krasselt M; Wagner U; Nguyen P; Pietsch C; Boldt A; Baerwald C; Pierer M; Seifert O
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI180-SI188. PubMed ID: 35143648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study.
    Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
    Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
    Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Frodlund M; Nived P; Chatzidionysiou A; Södergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
    Vaccine; 2023 May; 41(20):3247-3257. PubMed ID: 37076360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
    Park JK; Lee EB; Shin K; Sung YK; Kim TH; Kwon SR; Lee MS; Hong SJ; Choi BY; Lee SS; Back HJ;
    J Korean Med Sci; 2021 Mar; 36(12):e95. PubMed ID: 33783147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
    Zheng YQ; Li HJ; Chen L; Lin SP
    Sci Rep; 2022 Oct; 12(1):17955. PubMed ID: 36289319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
    Auroux M; Laurent B; Coste B; Massy E; Mercier A; Durieu I; Confavreux CB; Lega JC; Mainbourg S; Coury F
    Joint Bone Spine; 2022 Oct; 89(5):105380. PubMed ID: 35490940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
    Friedman MA; Curtis JR; Winthrop KL
    Ann Rheum Dis; 2021 Oct; 80(10):1255-1265. PubMed ID: 34493491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
    Zamani B; Moradi Hasan-Abad A; Piroozmand A; Dehghani M; Arfaatabar M; Motedayyen H
    Immun Inflamm Dis; 2023 May; 11(5):e858. PubMed ID: 37249277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
    Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
    Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
    Raptis CE; Berger CT; Ciurea A; Andrey DO; Polysopoulos C; Lescuyer P; Maletic T; Riek M; Scherer A; von Loga I; Safford J; Lauper K; Möller B; Vuilleumier N; Finckh A; Rubbert-Roth A
    Front Immunol; 2022; 13():1016927. PubMed ID: 36311791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of COVID-19 Vaccines in Patients with SLE.
    Tang W; Gartshteyn Y; Ricker E; Inzerillo S; Murray S; Khalili L; Askanase A
    Curr Rheumatol Rep; 2021 Nov; 23(11):79. PubMed ID: 34767100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
    Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU
    medRxiv; 2021 May; ():. PubMed ID: 34013285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
    Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.